Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasm Metastasis 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Kaposi 1Melanoma 1Lymphopenia 1HIV Infections 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1AIDS-related Kaposi sarcoma 1

Interventions

pembrolizumab 8avelumab 6fludarabine 3Radiotherapy 3Radiation 3Cyclophosphamide 3cemiplimab 2atezolizumab 2aldesleukin 2Interleukin-2 2Interferon-beta 2ALT-803 2talimogene laherparepvec 1poly ICLC 1pentetreotide 1interferon gamma-1b 1epacadostat 1efineptakin alfa 1durvalumab 1cabozantinib 1bempegaldesleukin 1TTI-621 1Paclitaxel 1Nivolumab 1Interferon-gamma 1Influenza Vaccines 1Immunotherapy 1High-Intensity Focused Ultrasound Ablation 1Carboxylesterase 1B7-H1 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Merkel Cell × efineptakin alfa × Clear all
NCT03901573 2025-10-22

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

NeoImmuneTech

Phase 1/2 Terminated
31 enrolled 12 charts
Dermatologic

Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡